首页> 美国卫生研究院文献>Brain Circulation >Clinical application of oligodendrocyte precursor cells for cell-based therapy
【2h】

Clinical application of oligodendrocyte precursor cells for cell-based therapy

机译:少突胶质前体细胞在基于细胞治疗中的临床应用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Oligodendrocyte precursor cells (OPCs), which give rise to mature oligodendrocytes (OLs), play important roles in maintaining white matter function. Even during the adulthood period, OPCs comprise roughly 5% of all cells in the forebrain and retain a capability to become myelinated OLs. Recently, OPCs have been proposed as a novel source for cell-based therapy. For the purpose, OPCs can be obtained from embryonic stem cells, induced pluripotent stem cells, and directly converted cells derived from patients. Here, we will provide a brief review of the potential of using OPCs as a cell-based therapy for treating various neurological diseases.
机译:产生成熟的少突胶质细胞(OL)的少突胶质细胞前体细胞(OPC)在维持白质功能中起重要作用。即使在成年期,OPC仍占前脑所有细胞的5%,并保留成为髓鞘OL的能力。近来,OPC已经被提出作为基于细胞的治疗的新来源。为此,OPC可以从胚胎干细胞,诱导的多能干细胞和直接转化自患者的细胞中获得。在这里,我们将简要介绍将OPC用作治疗多种神经系统疾病的细胞疗法的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号